Reuters
19 Nov 2026, 06:26 UTC · 12h ago
Novartis targets 5% annual sales growth through 2031
Impact · against what's priced in
Novartis provides a concrete long-term valuation anchor by targeting 5% annual sales growth through 2031. This establishes a baseline for EPS growth expectations over the next five years.
- NVS+0.40
No priced-in read yet
- In context
The target of 5% annual sales growth through 2031 provides a specific long-term trajectory for revenue that the market can now model for future valuation.
Read from the article alone
- Actual

Top 1 mover · tap to explore




